International audienceIntroduction: Using a biologic disease-modifying antirheumatic drug (bDMARD) as monotherapy in clinical practice for patients with rheumatoid arthritis (RA) is common and recognised by health authorities although current guidelines recommend to combine them with conventional synthetic (cs)DMARDs. This study mainly aimed to search for real-life factors influencing the use of tocilizumab as MONO or in combination (COMBO).Methods: In this non-interventional, prospective, national, multicentre study, data were collected every 3 months over a 12-month period in RA patients starting tocilizumab. The proportion of monotherapy patients was described, together with significant explicative factors.Results: Among the 577 analysed...
Objective. The ACT-MOVE study assessed the real-world efficacy and safety of s.c. tocilizumab (TCZSC...
Objective To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor i...
Objectives: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biolog...
International audienceIntroduction: Using a biologic disease-modifying antirheumatic drug (bDMARD) a...
OBJECTIVES: To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-mod...
OBJECTIVE: To assess the long-term safety, tolerability, and effectiveness of tocilizumab (TCZ) as m...
OBJECTIVES To observe patients with rheumatoid arthritis (RA) treated with the interleukin-6 rece...
Objective To observe patients with rheumatoid arthritis (RA) treated with the interleukin-6 rece...
Objectives To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-modi...
Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheu...
Background: Previous studies in patients with rheumatoid arthritis (RA) have shown that switching to...
This was an exploratory analysis comparing the safety and efficacy of tocilizumab monotherapy with t...
The latest revision of the European League Against Rheumatism (EULAR) recommendations for rheumatoid...
Objective: To compare the effectiveness of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibi...
Objectives. The aim of this pooled analysis of the TOZURA study programme was to evaluate the effica...
Objective. The ACT-MOVE study assessed the real-world efficacy and safety of s.c. tocilizumab (TCZSC...
Objective To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor i...
Objectives: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biolog...
International audienceIntroduction: Using a biologic disease-modifying antirheumatic drug (bDMARD) a...
OBJECTIVES: To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-mod...
OBJECTIVE: To assess the long-term safety, tolerability, and effectiveness of tocilizumab (TCZ) as m...
OBJECTIVES To observe patients with rheumatoid arthritis (RA) treated with the interleukin-6 rece...
Objective To observe patients with rheumatoid arthritis (RA) treated with the interleukin-6 rece...
Objectives To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-modi...
Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheu...
Background: Previous studies in patients with rheumatoid arthritis (RA) have shown that switching to...
This was an exploratory analysis comparing the safety and efficacy of tocilizumab monotherapy with t...
The latest revision of the European League Against Rheumatism (EULAR) recommendations for rheumatoid...
Objective: To compare the effectiveness of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibi...
Objectives. The aim of this pooled analysis of the TOZURA study programme was to evaluate the effica...
Objective. The ACT-MOVE study assessed the real-world efficacy and safety of s.c. tocilizumab (TCZSC...
Objective To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor i...
Objectives: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biolog...